Effects of transcutaneous auricular nerve stimulation on thalamic relay: A randomized brain imaging study in chronic low back pain patients.

Brain ResJun 26, 2026 (epub)
Clinical ResearchNeurology

Yuefeng Wu, Qiao Kong, Valeria Sacca et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous greater auricular nerve stimulation (tGANS) on thalamocortical circuits in 70 patients with chronic low back pain (cLBP). Both interventions significantly reduced pain intensity and interference scores, with no notable differences between groups. Notably, taVNS was associated with decreased functional connectivity and gray matter volume in specific brain regions.

Key findings

  • Both taVNS and tGANS significantly reduced pain intensity and bothersomeness scores.
  • taVNS led to significant decreases in static functional connectivity between the MD thalamus and the left postcentral gyrus.
  • Gray matter volume of the left postcentral gyrus decreased after taVNS treatment.
  • Decreased dynamic functional connectivity between the VPL and postcentral gyrus correlated with reduced pain intensity.

Why it matters

Understanding the effects of taVNS and tGANS on brain connectivity may inform new therapeutic strategies for managing chronic pain, potentially improving patient outcomes in chronic low back pain.

Source

Published in Brain Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.